Article-5(3) opinions

  • Email
  • Help

This page lists the opinions drawn up by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) under Article 5(3) of the Regulation establishing the EMA, concerning any scientific matter related to the evaluation of medicines for use in humans.

The Committee must draw up such an opinion at the request of the Executive Director of the EMA or of the European Commission. It may also draw up an opinion following a request from a Member State.

Where the scientific issue concerns both human and veterinary medicines, the Committee may adopt a common opinion with the Committee for Medicinal Products for Veterinary Use (CVMP).

Requests for this type of scientific opinion fall under Article 5(3) of Regulation (EC) No 726/2004.

Table of contents


Review of propylene glycol in medicinal products for children

Back to top

Document(s) Language Status First published Last updated Effective Date
Assessment report for Article-5(3) procedure: Propylene glycol in medicinal products for children (English only) adopted 27/03/2014    

Review of GLP-1-based therapies

Back to top

Document(s) Language Status First published Last updated Effective Date
Assessment report for Article-5(3) procedure: GLP-1-based therapies (English only) adopted 01/08/2013    

Review of Octagam

Back to top

Document(s) Language Status First published Last updated Effective Date
Assessment report for Article-5(3) procedure: Octagam and associated names (English only) adopted 28/05/2013    

Review of teicoplanin-containing medicinal products

Back to top

Document(s) Language Status First published Last updated Effective Date
Assessment report for Article-5(3) procedure: Teicoplanin-containing medicinal products (English only) adopted 22/04/2013    

Supply chain for protamine-containing medicinal products

Back to top

Document(s) Language Status First published Last updated Effective Date
Assessment report for Article-5(3) procedure: Protamine-containing medicinal products (English only) adopted 06/12/2012    

Hypothesis on Pandemrix and development of narcolepsy

Back to top

Document(s) Language Status First published Last updated Effective Date
Assessment report for Article-5(3) procedure: Immunological differences of pandemic vaccines (review of hypothesis on Pandemrix and development of narcolepsy) (English only)   12/11/2012    

Non-selective non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk

Back to top

Anti-tuberculosis medicines used in children: review of dosing recommendations from the World Health Organization (WHO)

Back to top

Angiotensin-II-receptor antagonists and the risk of cancer

Back to top

Document(s) Language Status First published Last updated Effective Date
Assessment report for Article-5(3) procedure: Angiotensin II (type-1) receptor antagonists and risk of cancer (English only) adopted 09/02/2012    
Questions and answers on the review of angiotensin-II-receptor antagonists and the risk of cancer (English only)   20/10/2011    

Particles on silicone tubing of diphtheria and tetanus toxoid (DT) and diphtheria/tetanus toxoid/pertussis (DTwP) antigen bulk containers

Back to top

Potential off-label use of celecoxib in patients with familial adenomatous polyposis

Back to top

Presence of endotoxins in Baxter peritoneal dialysis solutions

Back to top

Document(s) Language Status First published Last updated Effective Date
Assessment report for Article-5(3) procedure: Presence of endotoxins in Baxter peritoneal dialysis solutions (English only)   20/12/2010    
Questions and answers on the presence of endotoxins in Baxter peritoneal dialysis solutions (English only)   17/12/2010    

Detection of unexpected viral DNA in live attenuated vaccines

Back to top

Bisphosphonates and osteonecrosis of the jaw

Back to top

Novel influenza (H1N1) outbreak: Tamiflu (oseltamivir) and Relenza (zanamivir)

Back to top

Conventional antipsychotics

Back to top

Antidepressants

Back to top

Document(s) Language Status First published Last updated Effective Date
Opinion of the CHMP pursuant to Article-5(3) of Regulation (EC) No 726/2004, on antidepressants (English only)   04/07/2008    
Letter on efficacy of antidepressants (English only)   18/03/2008    
CHMP assessment report on antidepressants under Article 5(3) of Regulation (EC) No 726/2004 (English only)   30/05/2008    

Medicinal products containing or derived from heparin

Back to top

Document(s) Language Status First published Last updated Effective Date
Opinion of the CHMP pursuant to Article-5(3) of Regulation (EC) No 726/2004, on heparins (English only)   06/06/2008    
CHMP assessment report for medicinal products containing or derived from heparin under Article 5(3) of Regulation (EC) No 726/2004 (English only)   30/05/2008    
Questions and answers on heparins (English only)   05/06/2008    

Potential risk of carcinogens, mutagens and substances toxic to reproduction when these substances are used as excipients of medicinal products for human use

Back to top

Adequacy of guidance on the elderly regarding medicinal products for human use

Back to top

Document(s) Language Status First published Last updated Effective Date
Adequacy of guidance on the elderly regarding medicinal products for human use (English only)   13/12/2006    

Non-selective non-steroidal anti-inflammatory drugs (NSAIDs)

Back to top